These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 20666954

  • 1. Levonorgestrel-intrauterine system effects on hemostasis and menstrual blood loss in women seeking contraception.
    Koh SC, Singh K.
    J Obstet Gynaecol Res; 2010 Aug; 36(4):838-44. PubMed ID: 20666954
    [Abstract] [Full Text] [Related]

  • 2. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia.
    Koh SC, Singh K.
    J Thromb Haemost; 2007 Jan; 5(1):133-8. PubMed ID: 17010149
    [Abstract] [Full Text] [Related]

  • 3. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding.
    Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O.
    Obstet Gynecol; 1997 Aug; 90(2):257-63. PubMed ID: 9241305
    [Abstract] [Full Text] [Related]

  • 4. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D, Schacht E.
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [Abstract] [Full Text] [Related]

  • 5. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F, Perniola G, Mossa B, Marziani R, Perniola F, Stragapede B, Napolitano C.
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [Abstract] [Full Text] [Related]

  • 6. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system.
    Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L.
    Contraception; 2009 Jul; 80(1):84-9. PubMed ID: 19501221
    [Abstract] [Full Text] [Related]

  • 7. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.
    Papp C, Schatz F, Krikun G, Hausknecht V, Lockwood CJ.
    Early Pregnancy (Cherry Hill); 2000 Oct; 4(4):230-9. PubMed ID: 11742418
    [Abstract] [Full Text] [Related]

  • 8. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
    Haimovich S, Checa MA, Mancebo G, Fusté P, Carreras R.
    Menopause; 2008 Oct; 15(5):1002-4. PubMed ID: 18451744
    [Abstract] [Full Text] [Related]

  • 9. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS.
    Andrade A, Wildemeersch D.
    Contraception; 2009 Feb; 79(2):134-8. PubMed ID: 19135571
    [Abstract] [Full Text] [Related]

  • 10. A biological model for the regulation of peri-implantational hemostasis and menstruation.
    Lockwood CJ, Schatz F.
    J Soc Gynecol Investig; 1996 Feb; 3(4):159-65. PubMed ID: 8796825
    [Abstract] [Full Text] [Related]

  • 11. Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.
    Guan YM, Carlberg M, Bruse C, Carlström K, Bergqvist A.
    Acta Obstet Gynecol Scand; 2002 May; 81(5):389-97. PubMed ID: 12027810
    [Abstract] [Full Text] [Related]

  • 12. Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system.
    Wildemeersch D, Rowe PJ.
    Contraception; 2005 Jun; 71(6):470-3. PubMed ID: 15914139
    [Abstract] [Full Text] [Related]

  • 13. The Effect of Levonorgestrel on Fibrinolytic Factors in Human Endometrial Endothelial Cells.
    Pakrashi T, Taylor JE, Nelson A, Archer DF, Jacot T.
    Reprod Sci; 2016 Nov; 23(11):1536-1541. PubMed ID: 27130232
    [Abstract] [Full Text] [Related]

  • 14. Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualization of human endometrial stromal cells.
    Lockwood CJ.
    Am J Obstet Gynecol; 2001 Apr; 184(5):798-804; discussion 804-5. PubMed ID: 11303186
    [Abstract] [Full Text] [Related]

  • 15. von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.
    Schved JF, Gris JC, Arnaud A, Martinez P, Sanchez N, Wautier JL, Sarlat C.
    J Lab Clin Med; 1992 Sep; 120(3):411-9. PubMed ID: 1517688
    [Abstract] [Full Text] [Related]

  • 16. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [Abstract] [Full Text] [Related]

  • 17. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection.
    Rauramo I, Elo I, Istre O.
    Obstet Gynecol; 2004 Dec; 104(6):1314-21. PubMed ID: 15572496
    [Abstract] [Full Text] [Related]

  • 18. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.
    Magalhães J, Aldrighi JM, de Lima GR.
    Contraception; 2007 Mar; 75(3):193-8. PubMed ID: 17303488
    [Abstract] [Full Text] [Related]

  • 19. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN.
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [Abstract] [Full Text] [Related]

  • 20. Progestin-releasing intrauterine systems.
    Luukkainen T, Pakarinen P, Toivonen J.
    Semin Reprod Med; 2001 Dec; 19(4):355-63. PubMed ID: 11727177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.